Upcoming Webcasts:

May 17, 2022
2022 RBC Capital Markets Global Healthcare Conference
11:30 a.m. ET / 5:30 p.m. CET
Click here to view webcast 

Webcast Archive:

March 31, 2022
Guggenheim Genomic Medicines & Rare Disease Day
8:00 a.m. ET / 2:00 p.m. CET
Click here to view webcast 

March 28, 2022
Stifel 2022 CNS Days 
12:00 p.m. ET / 6:00 p.m. CET
Click here to view webcast 

March 9, 2022
Cowen Healthcare Conference 2022 
12:50 p.m. ET / 6:50 p.m. CET
Click here to view webcast 

February 17, 2022
11th Annual SVB Leerink Global Healthcare Conference
8:40 a.m. ET / 2:40 p.m. CET
Click here to view webcast 

December 16, 2021
uniQure Initial HD Clinical Update 
8:30 a.m. ET / 2:30 p.m. CET
Click here to view webcast 

June 22, 2021
uniQure's Virtual Research & Development Day 
8:30 a.m. ET / 2:30 p.m. CET
Click here for replay

Investor Downloads:

2021 Dutch Statutory IFRS Financials 

EAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B

ESGCT 2021 - Pre-Clinical Proof of Concept of an AAV5-GLA Gene Therapy for Fabry Disease Resulting in Cross-Correction in GLA KO Mice and Non-Human Primates in Target Organs

ISTH 2021 - Clinical Outcomes in Adults with Hemophilia B With Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data from the HOPE-B Trial

ISTH 2021 - Liver Safety Case Report from the Phase 3 HOPE-B Gene Therapy Trial in Adults with Hemophilia B

ISTH 2021 - 52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-Severe Hemophilia B: Data from the Phase 3 HOPE-B Gene Therapy Trial 

uniQure 2021 Research & Development Day Presentation

ASGCT 2021 - Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6 Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec

Gene Therapy Information (PDF)